Abstract
BACKGROUNDOsteosarcoma is the most common primary bone malignancy. We meta-analyzed the prognostic value of altered miRNAs in patients with osteosarcoma.METHODSSources from MEDLINE (from inception to August 2016) and EMBASE (from inception to August 2016) were searched. Studies of osteosarcoma with results of miRNA and studies that reported survival data were included and two authors performed the data extraction independently. Any discrepancies were resolved by a consensus. The outcome was overall survival and event-free survival assessed using hazard ratios (HRs).RESULTSAfter reviewing the full text of 65 articles, 25 studies including 2,278 patients were eligible in this study. The pooled HR for deaths was 1.40 (95% confidence interval [CI] 1.01-1.94, p=0.04) with random-effects model (χ2=113.08, p<0.00001, I2=79%) for patients of osteosarcoma with lower expression of miRNA. However, the pooled HR for events was not significant (HR 0.97, 0.63-1.48, p=0.87, χ2=72.65, p<0.00001, I2=79%). In pathway analysis of miRNAs, miRNA449a, 199-5p, 542-5p have common target genes.CONCLUSIONSExpression level of miRNA in patients of osteosarcoma is important as a prognostic factor.
Highlights
Osteosarcoma is the most common primary bony malignancies and first leading cause of sarcoma-related deaths in children and young adults
The pooled hazard ratios (HRs) for deaths was 1.40 (95% confidence interval [CI] 1.01-1.94, p=0.04) with random-effects model (χ2=113.08, p
Expression level of miRNA in patients of osteosarcoma is important as a prognostic factor
Summary
Osteosarcoma is the most common primary bony malignancies and first leading cause of sarcoma-related deaths in children and young adults. It mainly occurs in metaphyseal area of distal femur and proximal tibia. For localized osteosarcoma which can be totally resectable, the five-year survival rate increases up to 70% [2]. Excavating novel prognostic biomarkers of osteosarcoma is strongly needed to detect tumor at early stage. They will contribute to select better treatment options in earlier stages and predict the outcome more accurately. Osteosarcoma is the most common primary bone malignancy. We meta-analyzed the prognostic value of altered miRNAs in patients with osteosarcoma
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
